- ST Pharm received a comprehensive B+ as a result of the 2022 ESG evaluation from KCGS (Korea Institute of Corporate Governance and Sustainability).

- Since KCGS' evaluation applies the same evaluation criteria regardless of the size of the company, it is relatively advantageous for large holding companies or large conglomerates.